Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2021

He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, Hammarström M, Margolin S, Thorén L, Wengström Y, Borgquist S, Hall P, Czene K

Abstract excerpt

BACKGROUND: Guidelines regarding whether tamoxifen should be prescribed based on women's cytochrome P450 2D6 (CYP2D6) genotypes are conflicting and have caused confusion. This study aims to investigate if CYP2D6 metabolizer status is associated with tamoxifen-related endocrine symptoms, tamoxifen discontinuation, and mammographic density change. PATIENTS AND METHODS: We used data from 1440 healthy women who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Pharmaceutical Preparations

Share to Tamoxifen

Source

Identifiers

PMID: 34284099
DOI: 10.1016/j.annonc.2021.07.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.PMID 34284099Read ↗

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.Semantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.Semantic proximity Read ↗

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Semantic proximity Read ↗

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.Semantic proximity Read ↗

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.Semantic proximity Read ↗

Personalized tamoxifen: a step closer but miles to go.Semantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.